Targeting Src in breast cancer.

  title={Targeting Src in breast cancer.},
  author={Richard S. Finn},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  volume={19 8},
The clinical benefit of blocking oncogenic pathways in breast cancer and other malignancies has validated this approach and ushered in the era of molecularly targeted therapeutics. Src and its family members make up the largest group of nonreceptor tyrosine kinases. In laboratory models, these proteins have been shown to play a critical role in cellular growth and proliferation, angiogenesis, and invasion and metastasis. In addition, Src plays an important role in osteoclast activation and bone… CONTINUE READING